Immunovant Quarterly Income Statements Chart
Quarterly
|
Annual
Immunovant Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | ||||||||||||||
| research and development | 94,520,000 | 75,473,000 | 48,338,000 | 50,575,000 | 51,837,000 | 42,252,000 | 37,739,000 | 28,429,000 | 31,986,000 | 29,756,000 | 21,361,000 | 18,705,000 | 18,615,000 | 21,091,000 |
| acquired in-process research and development | 12,500,000 | 10,000,000 | ||||||||||||
| general and administrative | 19,782,000 | 18,808,000 | 13,215,000 | 15,402,000 | 12,422,000 | 11,775,000 | 11,875,000 | 11,946,000 | 15,241,000 | 11,515,000 | 16,289,000 | 11,181,000 | 10,302,000 | 10,549,000 |
| total operating expenses | 114,302,000 | 94,281,000 | 61,553,000 | 78,477,000 | 64,259,000 | 64,027,000 | 49,614,000 | 40,375,000 | 47,227,000 | 41,271,000 | 37,650,000 | 29,886,000 | 28,917,000 | 31,640,000 |
| interest income | -4,590,000 | -7,180,000 | -8,933,000 | -4,065,000 | -3,480,000 | -2,944,000 | -1,154,000 | |||||||
| other income | 1,258,000 | -28,000 | -1,094,000 | -464,000 | -356,000 | 1,757,000 | -793,000 | -354,000 | -44,000 | 114,000 | 84,000 | 626,000 | -680,000 | 503,000 |
| income before benefit for income taxes | -110,970,000 | -87,073,000 | -51,526,000 | -73,948,000 | -60,423,000 | -62,840,000 | -47,667,000 | -40,021,000 | -47,183,000 | -41,385,000 | -37,734,000 | -30,512,000 | -28,237,000 | -32,143,000 |
| benefit for income taxes | 152,000 | 77,000 | -108,000 | -11,000 | -991,000 | 387,000 | 261,000 | 352,000 | -12,000 | -31,000 | -41,000 | -79,000 | -367,000 | |
| net income | -111,122,000 | -87,150,000 | -51,418,000 | -73,937,000 | -59,432,000 | -63,227,000 | -47,928,000 | -40,373,000 | -47,171,000 | -41,385,000 | -37,703,000 | -30,471,000 | -28,158,000 | -31,776,000 |
| yoy | 86.97% | 37.84% | 7.28% | 83.13% | 25.99% | 52.78% | 27.12% | 32.50% | 67.52% | 30.24% | ||||
| qoq | 27.51% | 69.49% | -30.46% | 24.41% | -6.00% | 31.92% | 18.71% | -14.41% | 13.98% | 9.77% | 23.73% | 8.21% | -11.39% | |
| net income margin % | ||||||||||||||
| net income per common share – basic and diluted | -760 | -600 | -360 | -570 | -315 | -490 | -410 | -350 | -255 | -360 | -350 | -310 | -235 | -320 |
| weighted-average common shares outstanding – basic and diluted | 146,922,338,000 | 146,085,729,000 | 144,523,034,000 | 130,503,264,000 | 128,574,190,000 | 116,572,820,000 | 116,557,508,000 | 115,025,191,000 | 109,078,427,000 | 97,976,982,000 | 97,920,460,000 | |||
| interest expense |
We provide you with 20 years income statements for Immunovant stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Immunovant stock. Explore the full financial landscape of Immunovant stock with our expertly curated income statements.
The information provided in this report about Immunovant stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.